How to Discuss an IBD Clinical Trial With Your GI

Discuss an IBD clinical trial with your gastroenterologist before changing or pausing treatment. The study investigator determines protocol eligibility and manages research treatment, while your regular GI can compare the study with approved options and your prior disease course. The FDA advises people considering a clinical trial to talk with their health care provider. Bring the study identifier, consent form, visit calendar, treatment groups, and medication rules. The goal is a concrete comparison and communication plan, rather than a simple yes-or-no endorsement.

Give your GI a usable study summary

Bring the official title, National Clinical Trial number, site contact, sponsor, phase, purpose, and complete treatment map. Include randomization odds, placebo or active comparator, allowed background treatment, open-label extension, and duration. The National Institutes of Health explains that a protocol defines eligibility, procedures, treatments, protections, and information collection.

Also bring the screening and visit schedule. Highlight endoscopy, imaging, blood and stool testing, washouts, stable-dose rules, and prohibited medicines. A registry summary may omit operational detail, so use the consent form and documents supplied by the site. Ask your GI which missing information would change the medical comparison and send those questions back to the investigator.

Compare the trial with approved treatment options

Ask how each possible study group compares with options available outside research. Discuss current disease control, objective inflammation, prior response, complications, and the risk of delaying another treatment. The HHS volunteer questions recommend asking what alternatives exist and how their risks and possible benefits compare with the trial.

Review what is known and unknown about the investigational treatment. The consent process must disclose foreseeable risks, procedures, alternatives, and voluntary participation under FDA guidance. Ask your GI to identify medical concerns that the study team should address, while recognizing that neither clinician can predict your assignment or outcome. Record the comparison in plain language.

Review medication interruption and worsening disease

If the protocol requires a washout, stable dose, steroid taper, or prohibited medication, ask what risk the change creates in your specific history. IBD trial experts identify long washouts, placebo exposure, and protocol requirements that diverge from clinical practice as barriers in IBD research. Never alter medication before both teams agree on dates and monitoring.

Ask who will respond if symptoms, biomarkers, or another test worsen. Review rescue medication, treatment-failure rules, urgent unblinding, hospitalization, and withdrawal. Confirm who prescribes the next ordinary treatment and how quickly it can begin. The plan should cover screen failure as well as enrollment because formal screening may still change a preliminary match.

Define how the two teams will communicate

Ask the study site what information it can send your GI and obtain the necessary authorization. Decide who receives laboratory, imaging, endoscopy, medication, and adverse-event records. Your GI should know the study's after-hours contact, while the study should know where you receive urgent and ordinary care. Greater involvement of the participant's regular GI increased predicted willingness to enroll in an IBD trial preference study.

Clarify which clinician handles non-study prescriptions, vaccinations, infections, pregnancy questions, surgery, and unrelated health conditions. The trial team follows the protocol; your GI still manages care outside that boundary. Write the division of responsibility into your notes and update it when treatment or study status changes.

Plan the end before participation begins

Ask what happens after the last dose, early withdrawal, rescue treatment, or study closure. Investigational treatment may stop even after apparent benefit. Discuss insurance authorization, washout, record transfer, and the next approved option in advance. Participation remains voluntary, and the FDA confirms that participants may leave a trial.

Also ask when treatment assignment, personal findings, and aggregate results may be shared. Keep the site contact and study identifier in your medical record. A productive GI conversation ends with specific unresolved questions, a shared safety plan, and a transition route for every likely outcome. That preparation lets the research decision fit within continuous IBD care.

Schedule another GI discussion if screening reveals new inflammation, infection, laboratory abnormalities, or a medication rule that was absent from the original summary. Formal screening can change the medical comparison. The NIH screening guidance explains that new tests and samples may be part of screening. Updated findings deserve an updated decision rather than automatic continuation toward enrollment.

Bring the revised consent form and screening results to that conversation so both teams are working from the same information.